RDY vs. UTHR, SRPT, CTLT, VTRS, ROIV, ELAN, LEGN, VKTX, BMRN, and BGNE
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Catalent (CTLT), Viatris (VTRS), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Viking Therapeutics (VKTX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE). These companies are all part of the "pharmaceutical preparations" industry.
Dr. Reddy's Laboratories (NYSE:RDY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Dr. Reddy's Laboratories presently has a consensus price target of $81.00, indicating a potential upside of 18.66%. United Therapeutics has a consensus price target of $308.78, indicating a potential upside of 12.59%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than United Therapeutics.
United Therapeutics has a net margin of 42.05% compared to Dr. Reddy's Laboratories' net margin of 19.97%. Dr. Reddy's Laboratories' return on equity of 21.27% beat United Therapeutics' return on equity.
In the previous week, United Therapeutics had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 16 mentions for United Therapeutics and 3 mentions for Dr. Reddy's Laboratories. United Therapeutics' average media sentiment score of 0.86 beat Dr. Reddy's Laboratories' score of 0.60 indicating that United Therapeutics is being referred to more favorably in the news media.
United Therapeutics has lower revenue, but higher earnings than Dr. Reddy's Laboratories. United Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 12.5% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
United Therapeutics received 252 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 61.71% of users gave United Therapeutics an outperform vote while only 59.25% of users gave Dr. Reddy's Laboratories an outperform vote.
Dr. Reddy's Laboratories has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Summary
United Therapeutics beats Dr. Reddy's Laboratories on 12 of the 18 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
